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Asthma is characterized by the association of airway hyperresponsiveness (AHR), inﬂammation, and remodelling. The aim of
the present article is to review the pivotal role of airway smooth muscle (ASM) in the pathophysiology of asthma. ASM is the
main eﬀector of AHR. The mechanisms of AHR in asthma may involve a larger release of contractile mediators and/or a lower
release of relaxant mediators, an improved ASM cell excitation/contraction coupling, and/or an alteration in the contraction/load
coupling. Beyond its contractile function, ASM is also involved in bronchial inﬂammation and remodelling. Whereas ASM is a
target of the inﬂammatory process, it can also display proinﬂammatory and immunomodulatory functions, through its synthetic
properties and the expression of a wide range of cell surface molecules. ASM remodelling represents a key feature of asthmatic
bronchial remodelling. ASM also plays a role in promoting complementary airway structural alterations, in particular by its
synthetic function.
1.Introduction
The pathophysiology of asthma is characterized by the asso-
ciationofairwayhyperresponsiveness(AHR),inﬂammation,
and remodelling [1–3]. AHR is deﬁned by an increased
airway narrowing to a wide range of stimuli and is respon-
sible for recurrent episodes of wheezing and breathlessness.
Airway smooth muscle (ASM) is considered as the main
cell type involved in AHR [4, 5]. Bronchial inﬂammation
in asthma involves the recruitment of various inﬂammatory
cells including eosinophils, mast cells and T lymphocytes
[1]. However, the microlocalization of these cell types is
diﬀerent within the asthmatic ASM layer [6], suggesting
complex interactions between inﬂammatory cells and ASM
cells. Bronchial remodelling is described as an increased
thickening of the bronchial wall due to various structural
alterations including epithelial changes [7], subepithelial
membranethickening,enhancedextracellularmatrix(ECM)
deposition [8], mucous gland and goblet cell hypertrophy
and hyperplasia [9], neoangiogenesis [10], and increase in
ASM mass [11, 12]. This latter appears to be a key feature
of bronchial remodelling since increased ASM mass is asso-
ciated with a decrease in lung function in asthma [13–15].
The aim of the present article is thus to review the pivotal
role of ASM in the pathophysiology of asthma.
2. Role of ASM in AirwayHyperresponsiveness
AHR is usually described as either nonspeciﬁc or speciﬁc
AHR (Table 1). Nonspeciﬁc AHR is a common feature of
asthma, although it is also found in some patients suﬀering
from chronic obstructive pulmonary disease or allergic
rhinitis[16].StimuliinducingnonspeciﬁcAHRcanbedirect
or indirect (Table 1). Direct mediators stimulate ASM cell
membrane receptors. For instance, methacholine activates
muscarinic M3 receptor and induces ASM contraction
[17]. Conversely, indirect mediators ﬁrst stimulate one or
more intermediary cells, leading to the release of contractile
agonists, which, in turns, induce ASM contraction [18]. All
of these indirect challenges are associated with the release2 Journal of Allergy
Table 1: Stimuli used to assess airway hyperresponsiveness (AHR)
in vivo.
AHR Mechanisms Types Stimuli
Nonspeciﬁc Direct Pharmacological
Methacholine
[22]
Histamine [23]
Nonspeciﬁc Indirect Physical
Exercise [24]
Cold air, dry air
[25]
Eucapnic
hyperventilation
[26]
Hypo osmolar
solution [27]
Nonspeciﬁc Indirect Chemical
Adenosine
monophosphate
[28]
Mannitol [27]
Speciﬁc Indirect Allergen Pollens, House
dust mites [29]
of mast cell mediators, such as prostaglandins, PGD2 and
PGF2α, or histamine, which, respectively, activate ASM cell
membrane receptors TP, FP, and H1 [19]. For instance, acute
and intense exercise induces airway dehydration, increasing
osmolarity of the airway surface liquid [20]. Cell volume
shrinkage and restoration release both mast cell mediators
and acetylcholine from nerves [20]. On the other hand,
speciﬁc AHR is limited to allergic asthmatics. In such case,
the stimulus is an allergen against which the patient is
speciﬁcally sensitized. The mechanism of ASM contraction
also involves the release of mast cell mediators. Speciﬁc AHR
measurement is restricted to clinical trials or detection of
occupational diseases. Indeed, allergen-speciﬁc stimulation
can enhance nonspeciﬁc AHR [21] and induce a late phase
response [19].
The mechanisms of AHR in asthma may involve (i) a
larger release of contractile mediators, (ii) a lower release
of relaxant mediators, (iii) an improved ASM cell excita-
tion/contraction coupling, and/or (iv) an alteration in the
contraction/load coupling.
2.1. Larger Release of Contractile Mediators. The contraction
of ASM can be induced by a variety of extracellular messen-
gers, which act through interaction with speciﬁc receptors
at the site of the plasma membrane of ASM (Table 2).
These contractile agonists, either inﬂammatory mediators
or neurotransmitters, are released at high concentrations in
asthmatic bronchi, especially regarding mast cell mediators
following indirect challenges [19]. For instance, mast cells
release tryptase, which increases ASM cells cytosolic cal-
cium concentration [30], allowing them to contract after
activation of the protease activated receptor (PAR) type
2, expressed on their membrane [31]. Mast cells, but
also eosinophils, produce contractile prostaglandins such as
PGF2α, PGD2, and thromboxane TXA2. The concentration
of these prostaglandins, and also that of histamine, is
Table 2: Contractile and relaxant mediators for ASM.
Types of mediators Actions Stimuli
Inﬂammatory Contraction
Histamine [23]
Tryptase [42]
Prostanoids (PGF2α,
PGD2, TXA2) [43]
Cysteinyl leukotrienes
(LTC4, LTD4, LTE4) [22]
Endothelin [44]
Neurotransmitters Contraction
Acetylcholine [45]
Neurokinine A [46]
Substance P [46]
Calcitonin Gene Related
Peptide [47]
Inﬂammatory Relaxation Prostanoids (PGE2, PGI2)
[48]
Neurotransmitters Relaxation
Adrenaline [49]
Noradrenaline [50]
Vasoactive Intestinal
Peptide [46]
increased in asthma [32]. Similarly, inﬂammatory cells also
produce both cysteinyl leukotrienes (LTC4, LTD4, LTE4),
which are also very potent direct contractile agonists of ASM
[33], and LTB4, which acts indirectly through the release of
TXA2 [34]. Such cysteinyl leukotrienes are also increased
in asthma [35], as well as endothelin [36], another direct
contractile agonist of ASM [37], produced by epithelial cells
or endothelial cells [38]. The release of contractile neuro-
transmitters, acetylcholine or tachykinins, is also known to
be higher in asthma [39, 40]. It is noteworthy that the loss of
epithelial barrier integrity commonlyassociated withasthma
mayincreaseexposureofASMtoinhaledcontractileagonists
[41].
2.2. Lower Release of Relaxant Mediators. AHR may also
be related to a lower release of relaxant agonists either
neurotransmitters or inﬂammatory mediators (Table 2).
Physiologically, the adrenergic innervation is sparse in the
ASM [51]. Moreover, a decreased number of β2-adrenergic
receptor sometimes associated with its desensitization has
been suggested in asthma following chronic medication with
short-acting β2-agonists [52]. A lower release of adrenaline
has also been demonstrated during asthma attacks [53].
The second important relaxing neurotransmitter is the
vasoactive intestinal peptide (VIP), which is colocalized with
acetylcholine [54]. However, the expression of VIP in the
asthmatic ASM is not decreased but surprisingly increased
[55]. By contrast, the production of PGE2, which is known
to relax ASM, is signiﬁcantly lower in asthmatic than in
nonasthmatic ASM cells [56]. Other cellular sources of PGE2
and other ASM relaxant, such as NO,may also be implicated.
2.3. Improved ASM Cell Excitation/Contraction Coupling.
Cytokines, such as IL-5 or IL-13, that are both increased in
asthma, do not contract ASM per se. In fact, IL-5 inducesJournal of Allergy 3
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Figure 1: Impaired ASM cell calcium homeostasis leading to enhanced proliferation in asthma. In severe asthmatic ASM cells, an altered
calcium homeostasis related to an increased inﬂux leads to phosphorylation and activation of CaMK-IV, that, in turns, successively
activates PGC-1α, NRF-1, and mtTFA. This transduction pathway results in an increase of mitochondrial biogenesis leading to enhanced
ASM proliferation [61]. In nonsevere asthmatic ASM cells, an altered expression and function of SERCA2 may account for the altered
calcium homeostasis, which leads to enhanced ASM proliferation [62]. Whatever the mechanism, such altered calcium homeostasis
enhances cell contractility. ASM: airway smooth muscle; CaMK-IV: calcium/calmodulin-dependent protein kinase IV; G: G protein; mtTFA:
mitochondrial transcription factor A; NRF: nuclear respiratory factor; PGC: peroxisome proliferator-activated receptor γ coactivator; PLC:
phospholipase C; SERCA: sarcoendoplasmic calcium pomp; SR: sarcoplasmic reticulum.
in vitro AHR to acetylcholine in isolated rabbit ASM tissue
and IL-13 reduces responsiveness to adrenaline in human
ASM cells [57, 58]. Moreover, mast cell-derived tryptase
induces AHR to histamine in vitro using human bronchi
from actively sensitized [59] or nonsensitized patients [60]
possibly via its enzymatic activity. However, such AHR
occurs after an initial calcium response and, thus, in the
absence of any spontaneous contraction. Indeed, AHR
may also depend on excitation/contraction coupling, which
associates two subsequent steps within the ASM cell, that is,
(i) the calcium response induced by extracellular messengers
and (ii) the calcium sensitivity of the contractile apparatus.
On the one hand, following extracellular stimulation,
ASM cytosolic calcium homeostasis is dependant on var-
ious components. For instance, the spontaneous return
to baseline of the cytosolic calcium concentration is dra-
matically delayed in asthmatic ASM cells [61]. Such a
delay can be related with an abnormal calcium entry [61]
and/or with a downregulated expression and function of
type 2 of the sarcoendoplasmic calcium pump, that is,
SERCA2 [62]( Figure 1). SERCA2 protein expression could
be experimentally decreased by IL-13 or TNF-α (TNFSF2)
[63]. Alternatively, the proinﬂammatory cytokine, IL-1β,
can increase CD38 (ADP-ribosyl cyclase) expression. Then,
CD38 increases cyclic ADP-ribose (cADPR) production,
which, in turns, activates ryanodin receptor (RyR), leading
to an increase in cytosolic calcium concentration [64–66].
In addition, calciumcompartmentalization could be another
determinant of airway responsiveness. In asthmatic ASM,
there could be a greater proportion of intracellular calcium
withinthedeepcytosolicspaceascomparedtothesuperﬁcial
subplasmalemmal space [67], leading to AHR. However,
such hypothesis needs to be conﬁrmed.
On the other hand, the calcium sensitivity of the
contractile apparatus can be increased, leading to a higher
contractileresponseafterasimilarASMintracellularcalcium
rise [68]. Two diﬀerent mechanisms have been described
according to the dependency or the independency from the
myosin light chain kinase/myosin light chain phosphatase
(MLCK/MLCP) ratio (Table 3). Regarding MLCK/MLCP-
dependent AHR, the level of MLCK is increased in asthmatic
ASM [69, 70]. The transcription factor CCAAT/enhancer
binding protein-α (C/EBP-α) expression is decreased within
the asthmatic ASM [71]. Since the promoter that regulates
the expression of MLCK contains several C/EBP-α binding
sites, such a deﬁcit in C/EBP-α has been proposed to account
for the increased expression of MLCK [72]. Nevertheless,
such increased expression of MLCK in asthmatic ASM needs
to be conﬁrmed since controversial ﬁndings have also been
reported [73, 74]. Regarding MLCK/MLCP-independent
AHR, calcium-independent PKCε inhibits calponin, an actin
thin ﬁlament-associated protein [75] that decreases calcium
sensitivity [76]. It also activates mitogen-activated protein
kinase (MAPK), which inhibits caldesmon, another actin4 Journal of Allergy
Table 3: Excitation/contraction coupling in ASM cells.
MLCK/MLCP balance Extracellular factors Intracellular factors Actions Consequences References
Dependent
CaMKII I: MLCK R [84]
β-adrenergic agonist PKA I: MLCK R [85]
β-adrenergic agonist PDE4D increase I: PKA C [86]
PKG A: MLCP R [87]
TNF-α (TNFSF2), IL-13 Rho-kinase I: MLCP C [87]
TNF-α (TNFSF2) Arachidonic acid A: Rho kinase C [88, 89]
TNF-α (TNFSF2) Arachidonic acid I: MLCP C [88, 90]
CPI-17 I: MLCP C [87]
C/EBP-α decrease I: MLCK C [72]
Independent
Caldesmon I: Myosin ATPase activity R [91]
Calponin I: Myosin ATPase activity R [92]
PKCε I: Caldesmon C [75]
PKCε I: Calponin C [75]
Derp1, LPS MAPK I: Caldesmon C [75, 93, 94]
TNF-α (TNFSF2), IL-13 Rho-kinase I: Calponin C [95]
CaMKII I: Calponin C [95]
HSP phosphorylated I: Contraction R [96, 97]
A: active; C: contracting; CaMKII: calcium/calmodulin-dependent protein kinase; CPI-17: 17-kDa PKC-potentiated inhibitory protein of PP1; C/EBPα:
CCAAT/enhancer binding protein α; Derp1: house dust mite allergen; HSP: heat shock protein; I: inhibit; IL-13: interleukin-13; LPS: lipopolysaccharide;
MAPK: mitogen-activated protein kinase; MLCK: myosin light chain kinase; MLCP: myosin light chain phosphatase; PDE4D: phosphodiesterase 4D, cAMP-
speciﬁc; PKA: cAMP-dependent protein kinase A; PKCε: protein kinase C ε; PKG: cGMP-dependent protein kinase G; R: relaxing; PP1: protein phosphatase
1; TNF-α: tumor necrosis factor α.
thin ﬁlament-associated protein [75] that also decreases
calcium sensitivity [76]. Alternatively, RhoA/Rho-kinase
signalling, which is increased in experimental asthma, in-
activates MLCP leading to MLCK/MLCP-dependent AHR
[77], and also inhibits calponin leading to MLCK/MLCP-
independent AHR. Such RhoA signalling can be reproduced
experimentally, using either the proinﬂammatory cytokine
TNF-α (TNFSF2), which activates RhoA [78], or IL-13,
which increases its expression in murine ASM [79].
Finally, the alteration in the dynamic properties of ASM
in asthma is still a matter of current debate. The maximal
velocity of shortening in ASM from sensitized animals is
signiﬁcantly greater than those in nonsensitized [80]a n d
may be a consequence of an increase in the activity of MLCK
[81] but is still controversial (see above). With respect to
force generation, although isometric force generated in vitro
is directly related to ASM mass in human bronchial ring
preparations [82], force generation from asthmatic ASM was
not found consistently increased [83].
2.4. Alteration in Contraction/Load Coupling. Like any mus-
cle, ASM may overcome loads that normally moderate ASM
shortening [98]. Two main categories of mechanical loads
thus apply to ASM: a preload, which is directly related to
lungelasticrecoilandlungvolume,andanafterload,whichis
determined by the shear modulus of the parenchyma and the
coupling of the lung to the airways [98]. Some of these loads
reside at the airway cellular/tissular level. Any alteration in
such loads against which the ASM contracts and/or in the
application of these loads to ASM will result in an alteration
in shortening and, hence, airway narrowing.
In asthma, several mechanisms may account for an alter-
ation in the contraction/load coupling [83, 98]s u c ha sa n
increase in lung elastic recoil pressure and a lung expansion
that increase the external load that opposes ASM shortening.
Indeed, loss of lung elastic recoil related to hyperinﬂation
has been demonstrated in acute asthma [99] and chronic
persistentasthmaevenwithoutemphysema[100].Moreover,
a coupling between lung parenchyma and airways occurs
through the attachments of elastic ﬁbers to the airway wall
[98]. In healthy individuals, periodic deeper inspirations
(DIs) dilate the airways because of an excessive relative
airway hysteresis as compared to parenchymal one [101]. In
contrast, loss of the beneﬁcial eﬀect of DI is sometimes con-
sidered as a hallmark of asthma [102, 103]. Why DI induces
bronchoconstriction in some asthmatic patients remains a
matter of debate. Leading hypotheses put forward include
neurohormonal mechanisms such as increase in cholinergic
tone [104] or mechanical mechanisms such as calcium-
dependent myogenic response of ASM [105]o rl o s so fi n t e r -
dependence between lung parenchyma and airways [106].
Such uncoupling of the forces of interdependence may also
be the result of airway inﬂammation and remodelling, espe-
cially thickening and/or oedema of the adventitia [107–109].
Moreover, stiﬀness of the airway wall may reduce the
ability of tidal breathing and DI to stretch ASM, leading
to latch bridges between actin/myosin and to a vicious
positive feedback [110, 111]. Finally, altered organization
and degradation of ECM proteins might also be less eﬀective
to moderate ASM shortening [83, 112, 113].
On the other hand, thickening of the airway wall and the
enhanced amount of ECM also increase airway stiﬀness andJournal of Allergy 5
Table 4: Mediators secreted and immunomodulatory proteins expressed by human ASM cells.
Factors References
Cell adhesion/costimulatory molecules, receptors
CD11a [117]
CD40 (TNFRSF5), CD40L (TNFSF5), CD44 [118]
CD80, CD86 [117]
OX40L (TNFSF4) [119]
Adhesion molecules: ICAM-1, VCAM-1 [118]
Major histocompatibility complex (MHC) II [120]
Toll-like receptors: TLR2, 3, 4 [121]
Chemokine receptors: CCR3, 7 [122]
Chemokine receptors: CXCR1, 3, 4 [122]
Receptors for IL-4, 6, 12, 13, 17, 22 and IFN-γ [116, 123]
Chemokines, cytokines, and growth factors
CCL2, 5, 7, 8, 11, 17, 19 [124–128]
CXCL8, 10 [129, 130]
CX3CL1 [55]
IL-2, 5, 6, 11, 12 [57, 131]
Interferon- (IFN-) γ [57]
Connective tissue growth factor (CTGF) [132]
Granulocyte macrophage-colony stimulating factor (GM-CSF) [133]
Stem cell factor (SCF) [134]
Transforming growth factor- (TGF-) β1[ 135]
Vascular endothelial growth factor (VEGF) [136]
ECM proteins
Chondroitin sulfate [137]
Collagens I, III, IV, V [137]
Decorin, elastin, ﬁbronectin, laminin, perlecan [137]
Thrombospondin [137]
Tissue inhibitor of MMPs- (TIMPs-) 1, 2 [138]
Enzymes
Matrix-metalloproteinases- (MMPs-) 9, 12 [139]
decrease airway compliance [114] that might enable the air-
ways to resist to dynamic compression. Moreover, deposition
of connective tissue also acts as mechanical impedance to
contraction [113]. Nevertheless, these theoretical advantages
of airway remodelling are largely overwhelmed by their
negative eﬀects [83].
3. Role of ASM in Bronchial Inﬂammation
While early studies regarding ASM function in asthma fo-
cussed on its contractile properties, a growing body of evi-
dence now consistently demonstrates that ASM is no longer
a sole target of the inﬂammatory process. Indeed, ASM
cell also displays proinﬂammatory and immunomodulatory
functions [115, 116], through its synthetic function and
its expression of a wide range of cell surface molecules,
integrins, costimulatory molecules, and Toll-like receptors
(Table 4). As a consequence, ASM can play an active
role, through an autocrine and/or a paracrine manner, in
the asthmatic inﬂammatory process. The molecular and
cellularmechanismsmodulatingASMcell/inﬂammatorycell
function will be reviewed below, with special attention to
those implicating mast cells and T lymphocytes, which are
known to inﬁltrate the asthmatic ASM layer [6].
3.1. ASM/Mast Cell Interaction. There is evidence that the
asthmatic ASM layer is inﬁltrated by an increased number
of mast cells [6, 55, 130, 140–147]. Some mast cells are
already present in nonasthmatic ASM including smokers
[148–152]. However, this mast-cell microlocalization within
the asthmatic ASM, termed mast cell myositis [153], appears
to be a speciﬁc feature of asthma, being absent in patients
suﬀering from eosinophilic bronchitis and healthy subjects
[140, 145]. Interestingly, the mast cell myositis is observed
in various asthma phenotypes, including eosinophilic and
noneosinophilic asthma [154], and also atopic and non
atopicasthma,evenifthenumberofmastcellsissigniﬁcantly
higher in the ASM of atopic asthmatics [142]. Moreover,
mast cell myositis is unchanged whether asthma is treated or
not [145, 146], or regardless of asthma severity [143, 145–
147].6 Journal of Allergy
(1) Mast cell chemotaxis
(3) Mast cell-ECM-ASM cell
adhesion
(2) Mast cell-ASM cell
adhesion
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Figure 2: Mechanisms underlying mast cell myositis in asthma. In asthma, the mechanisms leading to an inﬁltration of airway smooth
muscle (ASM) layer by mast cells, termed mast cell myositis, involve (1) mast cell chemotaxis towards the ASM bundle, (2) direct mast
cell-ASM cell adhesion, and (3) mast cell-extracellular matrix- (ECM-) ASM cell adherence. Upon mast cell activation, mast cells release
mediators which activate ASM cells, such as tryptase and TNF-α (TNFSF2). As a consequence, ASM cells produce and secrete chemotactic
factors for mast cells, leading to an autoactivation loop. Under stimulation by Th1, Th2, and/or proinﬂammatory cytokines, produced by
various inﬂammatory cells, ASM cells also secrete a wide range of mast cell chemotactic factors.
The mechanism of such a myositis has been ﬁrstly related
to the production of mast cell chemotactic factors by the
ASM itself, through an autoactivation loop [144]( Figure 2).
Indeed, upon activation, mast cells release tryptase and
proinﬂammatory cytokines, such as TNF-α (TNFSF2),
which stimulate the production of TGF-β1 and, to a lesser
extent, SCF by ASM cells, which in turns, induce mast cell
chemotaxis [144]. Moreover, ASM can promote mast cell
chemotaxisthroughthesecretionofawidearrayofchemoat-
tractants, upon stimulation by Th1 [130], Th2 [130, 155]o r
proinﬂammatorycytokines[55,144].Forinstance,ASMalso
produces functionally active CXCL10 [130], CXCL8 [155],
CCL11 [155], and CX3CL1 [55], even if, for CX3CL1, the
additional presence of VIP is necessary [55]. Taken together,
these ﬁndings support the view that mast cell migration
dependsonvarious mediatorssecreted by ASMandis closely
related to ASM inﬂammatory microenvironment.
Once present within the ASM bundle, mast cells can
adhere to ASM. This adhesion has been initially ascribed to a
cell-cellinteractioninvolvinganIgsuperfamilymember,that
is, cell adhesion molecule 1 (CADM1), previously known
as tumor suppressor in lung cancer 1 (TLSC-1 ) [156, 157]
(Figure 2). However, blocking CADM1 leads to only a partial
reduction in the adhesion of mast cells to ASM, suggesting
additional mechanisms are present [156]. Indeed, mast
cell-ASM adherence also involves cell-ECM-cell interaction
through type I collagen, CD44, and CD51 [2]( Figure 2).
This adhesion is improved under inﬂammatory conditions
or using asthmatic ASM cells [2]. These in vitro ﬁndings
are in agreement with ultrastructural analysis of asthmatic
ASM using electron microscopy, demonstrating the absence
of direct cell-cell contact between ASM and mast cells [6].
The majority of mast cells inﬁltrating the asthmatic
ASM layer are typically of the MCTC phenotype, containing
both tryptase and chymase [140, 158, 159]. Interestingly,
these mast cells inﬁltrate ASM in both large and small
airways, and exhibit marked features of chronic ongoing
activation [142, 143]. Such ﬁndings were also conﬁrmed by
ultrastructural analysis of ASM using electron microscopy
[6].However,littleisknownaboutthemechanismsbywhich
mast cell activation may occur within the ASM layer [160].
Mast cell degranulation may result from IgE-dependentJournal of Allergy 7
activation, especially in atopic patients [142]. However, IgE-
independent mechanisms have also been evoked, following
mast cell-ASM interaction through the complement C3a or
SCF [42, 157, 161, 162], for instance, or following bacterial
or viral infection through Toll-like receptors [160].
Taking into account the following characteristics: (i)
microlocalization of mast cells within the ASM layer, (ii)
mast cell adherence to the ASM, and (iii) mast cell activation
within the ASM, it is tempting to consider that a close func-
tional relationship may exist between these two cell types.
On the one hand, mast cells alter functional and phe-
notypic properties of ASM cells. Indeed, mast cell-derived
mediators contribute to AHR and ASM remodelling [12].
For instance, the major mast cell product, tryptase, induces
both ASM calcium response [30] and AHR to histamine
in vitro [60]o rin vivo [163]. Tryptase also increases ASM
cell-TGF-β1 secretion, which, in turns, promotes ASM cells
diﬀerentiation towards a contractile phenotype, character-
ized by an increase expression of α-actin and enhanced
contractility [42]. Interestingly, the number of mast cells
within the ASM layer is positively correlated with the degree
of AHR [140, 145], and with the intensity of α-smooth
muscle actin [42].
Mast cell myositis may also promote ASM remodelling.
However, although several mast cell products such as
tryptase are known to individually stimulate both DNA
synthesisandASMproliferation[164],coculturingASMand
mast cells does not increase proliferation [161]. Similarly,
ASM survival is not enhanced by mast cell interaction [161].
Both mast and ASM cell-derived CCL19 mediate ASM
migration through ASM CCR7 activation [128]. By contrast,
CCL11/CCR3-mediated ASM cell migration was inhibited
by mast cells [165]. No correlation was found between the
number of mast cells in the ASM and ASM mass, supporting
the modest role of mast cells in ASM remodelling [142].
On the other hand, ASM cells alter functional and phe-
notypic properties of mast cells. Indeed, ASM cells can pro-
mote mast cell survival, hence providing a favorable mi-
croenvironnement for mast cells [157]. They also enhance
their proliferation, through a mechanism involving a coo-
perative interaction between ASM membrane-bound SCF,
soluble IL-6, and mast cell-expressed CADM1 [157]. ASM
cells-derived ECM proteins may also promote mast cells
diﬀerentiation towards a ﬁbroblastoid phenotype, charac-
terizedbytheexpressionofﬁbroblastmarkersandﬁbroblast-
like morphology. This feature seems to be speciﬁc of mast
cells within the ASM layer, since ﬁbroblast markers are not
expressed in submucosal mast cells [147].
3.2. ASM/T Cell Interaction. Up to now, only few studies
have documented T cell inﬁltration within the ASM layer
in asthma. CD4+ T cell microlocalization within ASM layer
was ﬁrst reported in an elegant experimental rat asthma
model [166]. This ﬁnding was further conﬁrmed in human
asthmatics [6, 15] and is related to asthma severity [15].
Moreover, this feature appears to be speciﬁc of asthma, since
T cells were not found in the ASM layer of control subjects,
but within and beneath the epithelium [15]. As compared
to mast cell ASM inﬁltration, there is a relative paucity of
T cells within the ASM layer [6, 140]. However, ASM cells
are able to produce appropriate chemotactic factors for T
cells, such as CCL5 [125]. In this respect, a possible role for
mast cell chymase has been suggested since this protease is
known to inhibit T cell adhesion to nonasthmatic ASM cells
in vitro [167]. Nonetheless, close contact were pointed out
betweenASMcellsandTcellsinasthmaexvivo[6,15],hence
suggesting cell-cell adherence between these two cell types.
Lazaar and coworkers originally demonstrated that acti-
vated T cells can adhere in vitro to resting ASM cells
from nonasthmatic patients and that such an adhesion was
enhanced when ASM cells were primed with proinﬂam-
matory cytokines such as TNF-α (TNFSF2) [118]. These
ﬁndings were independently further conﬁrmed [117]. This
adhesion involves CD44, intercellular cell adhesion molecule
1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1)
expressed by ASM cells, and CD44, lymphocyte function-
associated antigen 1 (LFA-1) and very late antigen 4 (VLA-4)
expressed by T cells [118]. More recently, nonasthmatic ASM
cells, pulsed to the superantigen staphylococcal enterotoxin
A (SEA), have been shown to adhere to T cells by presenting
the SEA via their MHC class II [168]. Although ASM
cells express MHC class II, constitutively as well as under
stimulation [117, 120], they are not classically considered
as an antigen-presenting cell. Consequently, these ﬁndings
support an emerging role of ASM cell as an immunomod-
ulatory cell. However, except for VCAM-1, which forms
clusters in the asthmatic ASM ex vivo suggesting VCAM-
1 mediated intercellular signalling, the role of the above
molecules in adherence between T cell and ASM cell from
asthmatic patients has not yet been considered. Two other
ASM cell-surface molecules, CD40 (TNFRSF5) [117, 169–
171] and OX40 ligand (TNFSF4) [119, 171, 172], both
expressed in asthmatic and nonasthmatic ASM cells, may
also play a role in promoting ASM cell-T cell adherence.
These costimulatory cell-surface molecules, members of the
TNFsuperfamily,respectively,bindtoCD40L(TNFSF5)and
OX40 (TNFRSF4) on activated T cells [173, 174]. However,
their role in the adherence of T cells to asthmatic ASM
remains to be investigated.
Close interaction between T cells and ASM cells may
lead to stimulatory cross-talk between these two cell types,
but little is known about the functional consequences of
such an interaction. On the one hand, T cells may alter
functional properties of ASM cells. In this connection,
T cells alter ASM contractile phenotype, enhancing ASM
contractility to acetylcholine and reducing its relaxation to
isoproterenol in isolated rabbit ASM tissue [117]. T cells may
also drive ASM remodelling, in particular ASM hyperplasia
[15, 118, 166]. Indeed, in an experimental rat asthma model,
adoptively transferred CD4+ T cells from OVA-sensitized
rats increases ASM mass, which is both associated with
an increased ASM proliferation and decreased apoptosis
ex vivo [166]. Such an increased ASM proliferation and
decreased apoptosis was conﬁrmed in vitro only upon direct
CD4+ T cells-ASM cells contact, highlighting the need for
close cellular interaction between these two cell types [166].
These observations are in agreement with a previous study8 Journal of Allergy
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Figure 3: Representative optic microscopic from bronchial sections stained with Haematoxylin, Eosin, and safranin stain were obtained
from (a) a control subject or (b) an asthmatic patient (printed from Bara et al. [12], with permission of European Respiratory Journal
publisher) E: epithelium; G: mucous gland; SM: smooth muscle. Scale bars represent 50μm.
demonstratinginvitroaroleforTcellinASMDNAsynthesis
and proliferation in ASM cells from nonasthmatic patients
[118]. The role of T cells in driving ASM remodelling was
later conﬁrmed in human asthmatics [15]. Moreover, the
number of T cells inﬁltrating the asthmatic ASM correlates
with ASM mass [15]. Collectively, these ﬁndings suggest an
emerging role of T cells in both ASM hyperresponsiveness
and remodelling.
On the other hand, ASM cells may also alter functional
properties of T cells. Indeed, a direct contact between
CD4+ T cells and ASM cells also enhances T cell survival,
thus possibly contributing to the perpetuation of bronchial
inﬂammation [166]. Moreover, cultured human nonasth-
matic ASM cells are able to present superantigens via their
MHC class II molecules to resting CD4+ T cells [168],
which leads to CD4+ T cells activation, adherence between
these cells, and ﬁnally release of IL-13, that, in turns, leads
to increase in the contractile response to acetylcholine of
isolated rabbit ASM tissues [168].
4. Role of ASM in Bronchial Remodelling
ASM remodelling represents a key feature of asthmatic bron-
chial remodelling [12]( Figure 3). Indeed, many lines of
evidence demonstrate an increase in ASM mass in fatal
[175] and nonfatal asthma [15, 61, 70, 142]. However, ASM
remodelling is still insensitive to current asthma medications
[176] that are usually eﬀective in treating acute airway
narrowing and bronchial inﬂammation. Furthermore, ASM
cell plays also a role in promoting other bronchial remo-
delling structural alterations, in particular by virtue of
its synthetic function. For instance, ASM cells can release
biologically active TGF-β [177], which is involved in various
structuralalterationssuchasepithelialchanges,subepithelial
ﬁbrosis, mucus hypersecretion, goblet cell hyperplasia, and
angiogenesis [178].
The mechanisms underlying ASM remodelling involve
ASM hyperplasia, ASM hypertrophy, and an excessive depo-
sition of proteins of the ECM [12].
4.1. ASM Hyperplasia. Three mechanisms may account
for ASM hyperplasia, that is, (i) ASM cell proliferation,
(ii) reduced ASM cell apoptosis, and more recently (iii)
migration of myoﬁbroblasts within the ASM layer.
4.1.1. ASM Cell Proliferation. Compelling evidence now sug-
gests an excessive ASM cell proliferation in asthma both in
vitro [61, 62, 71, 179, 180]a n din vivo [15, 181]. However,
before these two recent studies [15, 181], the number of pro-
liferative ASM cells in vivo was a matter of debate since the
number of PCNA or Ki67 positive ASM cells was unchanged
in asthmatic bronchial samples [6, 70]. The reason for this
discrepancy is apparently related with the ﬁxation process.
A wide array of mitogenic factors are known to promote
ASM cell proliferation in vitro, including growth factors,
cytokines, chemokines, inﬂammatory mediators, enzymes,
ECM components, reactive oxygen species, and mechanical
stress (Table 5). Such mitogenic factors promote ASM cell
proliferationbyactivatingpathwaysinvolvingeitherreceptor
tyrosine kinase (RTK) or receptor coupled to heterotrimeric
Gproteins(GPCR)[182].Uponactivationofthesereceptors,
downstream transduction pathways usually involve Ras,
phosphatidylinositol 3-kinase (PI3K) or MAPK/ERK kinase
(MEK) and extracellular signal-regulated kinase (ERK),
which in turns induce cyclin D1 expression [182].
However, asthmatic ASM cells can also proliferate faster
in vitro than nonasthmatic ASM cells irrespective of extra-
cellular stimuli [179], hence supporting the view that an
intrinsic ASM abnormality does exist in asthma. In this re-
spect, ASM tissue-speciﬁc decreased levels of C/EBPα were
found in asthmatics and could explain enhanced prolifera-
tion [71], through downregulation of the cell-cycle inhibitor
p21. In addition, steroids are less eﬀective in asthmatic ASM
cells, since C/EBPα expression is impaired [71]. An alterna-
tive, or complementary, ASM tissue-speciﬁc explanation
for the increased asthmatic ASM cell proliferation is an
alteration of ASM calcium homeostasis. In severe asthma,
an abnormal extracellular calcium entry leads to subsequent
activation of peroxisome proliferator-activated receptor γJournal of Allergy 9
Table 5: Mitogenic factors for human ASM cells.
Classiﬁcation References
Growth factors/cytokines/chemokines
Platelet-derived growth factor (PDGF) [211]
Fibroblast growth factor (FGF) [212]
Epidermal growth factor (EGF) [213]
T u m o rn e c r o s i sf a c t o r -( T N F - )α (TNFSF2) [214]
Transforming growth factor- (TGF-) β1
(controversial) [215, 216]
CCL3, 5, 11 [186]
CXCL8 [186]
Inﬂammatory mediators
Histamine [217]
Endothelin-1 [218]
Thromboxane A2 [219]
Sphingosine 1-phosphate [220]
Cysteinyl leukotrienes (LTC4, LTD4, LTE4) [221]
Enzymes
Tryptase [164]
Thrombin [222]
Elastase [223]
Matrix metalloproteinases [224]
ECM components
Fibronectin [225]
Collagen I [225]
Others
Reactive oxygen species [226]
Mechanical stress [227]
Brain derived neurotrophic factor (BDNF) [228]
coactivator-1α(PGC-1α),nuclearrespiratoryfactor-1(NRF-
1), and mitochondrial transcription factor A (mtTFA) [61].
This transduction pathway results in an increased mito-
chondrial biogenesis leading to enhanced ASM proliferation
[61]( Figure 1). Interestingly, such enhanced mitochondrial
biogenesis was not observed in other cell types, such
as endothelial or epithelial cells, highlighting the smooth
muscle speciﬁcity of such ﬁndings [61]. More recently, ASM
calcium homeostasis has also been shown to be impaired
in nonsevere asthma, via ad i ﬀerent mechanism [62]. Such
mechanism implicates reduced SERCA2 expression in both
n a t i v ea n dc u l t u r e dA S Mc e l l s ,b u to r i g i no fs u c hd e f e c ti n
asthmatic ASM remains unknown [183]( Figure 1).
4.1.2. Reduced ASM Apoptosis. Another explanation is to
consider that ASM hyperplasia may be due to an imbalance
between ASM proliferation and death. However, little is
known about processes that may counterbalance ASM
proliferation, such as apoptosis. Indeed, by contrast to the
substantial evidence supporting ASM proliferation, only few
studies have investigated ASM cells survival signals, ASM cell
spontaneous apoptosis, or their susceptibility to apoptosis
in response to proapoptotic factors. Most of the current
knowledgeaboutapoptoticpathwaysinASMoriginatesfrom
nonasthmatic ASM cells.
Cardiotrophin-1 [184], endothelin-1 [185], chemokines,
such as CCL3, CCL5, CCL11, and CXCL8 [186], or some
ECM components, including ﬁbronectin, laminin, and col-
lagens I and IV [187], inhibit nonasthmatic ASM cell apop-
tosis. ASM cells express in vitro the death receptors TNFR1
(TNFRSF1A), Fas (TNFRSF6), TRAILR1 (TNFRSF10A),
TRAILR2 (TNFRSF10B) [188], and stimulation of ASM cells
either with TNF-α (TNFSF2) [188, 189], soluble Fas ligand
(TNFSF6) [188], Fas antibody [189], or TRAIL (TNFSF10)
[188] induces cell apoptosis. Similarly, hydrogen peroxide-
exposure decreases ASM cells survival and is prevented
by overexpression of the small heat shock protein 27
(Hsp27), in part by upregulating glutathione levels [190].
ECM-degrading proteinase, such as neutrophil elastase, may
also induce ASM cell apoptosis by triggering detachment
from the ECM [191], which results in the withdrawal of
survival signals usually provided by some ECM compo-
nents [187]. Conversely, some ECM components, such as
decorin, may also induce ASM cells apoptosis in vitro [192].
Some treatments are also able to induce nonasthmatic ASM
cell apoptosis in vitro. Indeed, activation of peroxisome
proliferator-activatedreceptorγ (PPARγ),whichisexpressed
by ASM cells, by its synthetic ligand commonly used in
diabetes treatment, may also induce apoptosis [193]. More-
over, simvastatin, an HMG-CoA reductase inhibitor, has
recently been shown to trigger ASM cells apoptosis through
the intrinsic apoptotic pathway involving p53, enhanced
mitochondrial permeability, mitochondrial release of Smac
and Omi, and inhibition of mitochondrial ﬁssion, which in
turns leads to the activation of caspases 9, 7 and 3 [194].
However, the role of these diﬀerent mediators and signalling
pathways in asthmatic ASM cell survival remains unknown.
In asthma, the hypothesis of an imbalance between ASM
proliferation and apoptosis is mainly supported by a rat
model of T-cell driven remodelling [166]. Furthermore,
an increased expression of TRAIL (TNFSF10) has also
been shown ex vivo in asthmatic ASM following allergen
challenge, suggesting that this cytokine may play a role in
asthmatic ASM apoptosis [195]. Besides, active caspase 3
expression and double stranded DNA breaking were shown
ex vivo in ASM, in severe asthma, and in case of fatal
asthma, respectively [188]. Conversely, such ﬁndings were
notreportedinintermittentasthma[188]andBenayounand
coworkers failed to demonstrate active caspase 3 expression
ex vivo, irrespective of asthma severity [196]. In vitro,t w o
reports have also drawn negative results, showing no change
in spontaneous apoptosis within asthmatic ASM cells [61,
161]. As a consequence, further studies remain to be un-
dertaken to determine whether or not there is a change in
asthmatic ASM cell apoptosis.
4.1.3. Migration of ASM Cells and Myoﬁbroblasts. More re-
cently,ithasbeensuggestedthatmigrationofASMprecursor
cells, either located within the bronchial wall or derived
from peripheral blood ﬁbroblast progenitors, towards the
ASMbundlesmayalsoparticipateinASMhyperplasia[197].
Cellular migration is characterized by signiﬁcant cytoskeletal
remodelling with apparition of ﬁlopodia and lamellipodia to10 Journal of Allergy
increase directed movement along a concentration gradient
(chemotaxis) and/or nondirected movement (chemokinesis)
[197].
Migration of myoﬁbroblasts may participate in ASM
hyperplasia, by diﬀerentiating to ASM-like cells [197]. Such
an hypothesis was based on the microlocalization of myoﬁ-
broblastsbetweenASMbundles[6],whileanincreasednum-
berofmyoﬁbroblastshasbeendemonstratedwithinthelam-
ina reticularis, especially after allergen challenge [198], and
within the lamina propria [15].
However,theoriginofmyoﬁbroblastsremainsasourceof
debate and several hypotheses have been put forward. First,
myoﬁbroblasts may come from resident ﬁbroblasts that have
diﬀerentiated [199]o rf r o md e d i ﬀerenciation of ASM cells
themselves, which have migrated out of the ASM bundles
towards the lumen [199]. Indeed, a wide range of mediators
may promote in vitro human nonasthmatic ASM cell migra-
tion, such as cytokines, growth factors, chemokines, and
some ECM components [197]( Table 6). The major trans-
duction pathways so far identiﬁed for ASM cell migration
involve PI3K, Rho-kinase, MAPK, p38, and phosphorylation
of Hsp27 [197, 200]. Migration is also a strongly calcium-
dependent process [62, 128]. Thus, enhanced cell spreading,
which might reﬂect migration, was observed in asthmatic
ASM cells lacking SERCA2, while knocking down SERCA2
usingsmallinterferingRNAinnonasthmaticASMcellsleads
to earlier lamellipodia and enhanced cell spreading [62].
Whereas this ﬁrst study suggests that asthmatic ASM cells
might migrate more than nonasthmatic ASM cells [62], such
ﬁndings require further investigations, as well as addressing
directly ASM cell migration in vivo.
Myoﬁbroblasts can also originate from epithelial cells
undergoing phenotypic changes through epithelial-mesen-
chymal transition process [201–203]. Another hypothesis is
thatmyoﬁbroblastscomefromtherecruitmentofcirculating
bone-marrow-derived progenitors, termed ﬁbrocytes [204–
208]. Fibrocytes may be identiﬁed by the coexpression of the
stem cell marker CD34 and/or the panhematopoietic marker
CD45 and collagen-1 [209]. In this setting, a growing body
of evidence supports the concept of ﬁbrocytes traﬃcking to
the lung in asthma, both in mouse asthma models [204,
208] and in humans [204–207]. Indeed, ﬁbrocyte local-
ization has been found within the bronchial wall in
asthma [204], in particular, within the ASM bundles irre-
spective of asthma severity [206], close to the basement
membrane [207], in the lamina propria [206], or below
the epithelium [204, 208]. Fibrocytes diﬀerentiate into
myoﬁbroblasts, as evidenced by the concomitant expression
of ﬁbrocyte markers and α-smooth muscle actin [204, 205].
Mechanisms underlying such ﬁbrocyte chemotaxis to the
lung are in part mediated by ASM secreted-PDGF [206],
which also promotes ﬁbrocyte diﬀerentiation to myoﬁ-
broblast [205]. Besides, such chemotaxis might likewise
involve the chemokine receptors CXCR4, CCR2, CCR3,
CCR4, CCR5, CCR7, and the chemokines CCL3, CCL4,
CCL5, CCL7, CCL8, CCL11, and CCL13 [210]. Interest-
ingly, circulating ﬁbrocytes number is positively corre-
lated to the slope of the yearly decline in FEV1 [205],
Table 6: Promigratory factors for human ASM cells.
Factors References
Growth factors/cytokines/chemokines
FGF2, PDGF, TGF-α (TNFSF2), TGF-β [229, 230]
IL-1β, IL-17A, IL-17F, IL-22 [123, 230]
CCL5, 11, 19 [128, 231,
232]
CXCL8 [231]
Leukotriene E4 [233]
ECM components
Collagens I, III, V [233]
Fibronectin, laminin [233]
Enzymes
Matrix metalloproteinase- (MMP-)3 [234]
Others
Thrombin [235]
Urokinase plaminogen activator [236]
once again suggesting a role of ﬁbrocytes in ASM remod-
elling.
4.2. ASM Hypertrophy. Unlike ASM cell hyperplasia, evi-
dence for ASM cell hypertrophy in asthma remains a matter
of debate [6, 70, 74, 175]. In fact, increased ASM cell size
hasbeenreportedintissuespecimensfromintermittent[70],
mild-to-moderate [70], severe [70], fatal [175], and atopic
asthma [6]. However, conﬂicting ﬁndings were found in
mild-to-moderateasthma[74].Asaconsequence,ithasbeen
suggested that ASM cell hypertrophy might be a hallmark
of severe asthma status, since it can discriminate patients
with severe asthma from those with milder disease [70].
Interestingly, ASM cell hypertrophy was associated with an
increased amount of MLCK, which is involved in AHR [70].
Nevertheless, whether ASM hypertrophy is a condition suﬃ-
cient to induce AHR in asthma needs further investigations.
The underlying mechanisms of such ASM cell hyper-
trophy remain unknown in asthma. Cardiotrophin-1 [184],
serum deprivation [237], TGF-β [238], and endothelin-1
[185]c a nd r i v eA S Mc e l lh y p e r t r o p h yin vitro, and only in
nonasthmatic ASM cells. More recently, the role of miRNA-
26a, whose expression is increased by mechanical stretch, has
been highlighted in ASM cell hypertrophy [239]. However,
theroleofthesefactorsneedstobeclariﬁedinasthma,aswell
as the putative role of SERCA2, whose expression is known
to be also reduced in cardiac hypertrophy [240].
Two distinct transduction pathways can lead to ASM cell
hypertrophy [241]. Pathways can involve the mammalian
target of rapamycin (mTOR), 4E-binding protein (4E-BP),
the transcription factor eIF4E [242], and S6 kinase [243]
or the inhibition of glycogen synthase kinase- (GSK-) 3β
[244], for instance, by the serine/threonine kinase Akt [241].
However, involvement of such transduction pathways needs
tobefurtherinvestigatedinasthmaticASMcellhypertrophy.
4.3. Altered ECM within the ASM Layer. Alteration in ECM
represents another feature of ASM remodelling [12]. ECM is
increased in asthma [6], as a result of increased depositionJournal of Allergy 11
of ECM proteins by airway resident cells, such as epithelial
cells, ﬁbroblasts, myoﬁbroblasts, and ASM cells (Table 4).
Its composition is diﬀerent from that of nonasthmatics
[139]. Histological examination of asthmatic bronchial sam-
ples reveals enhanced deposition of ECM proteins in the
bronchial wall, such as collagens I, III, V, ﬁbronectin,
tenascin, hyaluronan, versican, laminin, lumican, and bigly-
can [245, 246], while collagen IV and elastin are decreased
[247]. However, conﬂicting ﬁndings have also been reported
regarding, the amount of collagen III [248, 249], collagen
IV [250]a n de l a s t i n[ 251] in the asthmatic bronchial wall.
Interestingly, ECM is also increased all around ASM cells
regardless of asthma severity [6, 252]. Such increase may be
due to decreased matrix metalloproteinases (MMPs), which
degrade ECM proteins, and/or increased tissue inhibitors of
MMPs(TIMPs).Thus,overexpressionofTIMP-1andTIMP-
2 may account for low MMPs activity in asthma [138]. The
proﬁle of ECM proteins produced in vitro by asthmatic ASM
cells is also diﬀerent from that of nonasthmatic ASM cells,
with more perlecan and collagen I, and less laminin-α1a n d
collagen IV [253].
Nevertheless, whether such alterations in ASM ECM
products contribute to modulate composition of the overall
bronchial ECM remains unknown. Conversely, increasing
evidence supports the role of ECM in modulating several
aspects of ASM function [254]. In fact, ﬁbronectin and colla-
gen I have been reported to promote ASM proliferation from
nonasthmatic donors in a dose-dependant fashion (Table 5),
whereas laminin inhibits growth [255]. Fibronectin, colla-
gens I, IV, and laminin also provide strong survival signals
for ASM cells and such an eﬀect is mediated at least in
part through the ﬁbronectin receptor/α5β1 integrin [187].
Moreover, ASM cell contact with membranes coated with
ECM components, such as ﬁbronectin, collagens III and V,
has been shown to enhance ASM migration [233]( Table 6).
Synthetic properties of ASM cells may also be modulated by
ECM components, such as IL-1β-dependent ASM secretion
of CCL5 and CCL11 [256]. More recently, ECM has been
involved in triggering ASM maturation to the contractile
phenotype upon serum deprivation [257].
5. Conclusion
ASM cell plays a pivotal position in the pathophysiology of
asthma as (i) a main eﬀector of AHR, (ii) a proinﬂammatory
andimmunomodulatorycellthroughitssyntheticproperties
and its expression of a wide range of cell surface molecules,
and (iii) a leading cell involving in bronchial remodelling.
If AHR and bronchial inﬂammation respond fairly well
to conventional therapy such as bronchodilators and anti-
inﬂammatory drugs, ASM remodelling remains insensitive
to these treatments [176]. Targeting the various functions
of ASM represents therefore a challenge for future asthma
treatments [5, 12, 176]. In particular, research needs to focus
on ways to prevent and/or reverse ASM remodelling. In
this connection, targeting mitochondrial biogenesis and/or
developing proapoptotic strategies to induce ASM cell death
may represent an attractive area of investigation. In this
respect, development of noninvasive tools for quantifying
ASM remodelling has received increasing attention in order
to evaluate on a long-term basis the eﬃcacy of such treat
ments [258].
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